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QUESTIONS
1. What is neurofibromatosis-1?
2. What was the rationale for the study?
3. How was the predictive model developed and validated?
4. What were the results?
5. What are the implications of the study?
A middle-aged patient presents with multiple café-au-lait macules 
(CALMs), cutaneous neurofibromas, and axillary freckling. You ably 
make a diagnosis of neurofibromatosis-1 (NF-1) and explain to the 
patient the genetics involved and that further evaluation for ocular 
manifestations is warranted (Boyd et al., 2009). As you explain the risk 
of malignancy—particularly the risk of malignant peripheral nerve-
sheath tumors (MPNST)—you ponder your patient’s individual risk 
for developing this tumor and what precautions the patient should 
be taking (Rasmussen et al., 2001).
Drawing on the understanding that early recognition of MPNST 
has the potential to be lifesaving (Levi et al., 2010) and that internal 
neurofibromas are an important risk factor for the development of 
MPNST, Sbidian et al. (2010, this issue) sought to determine the clinical characteristics that may predispose a patient 
to internal neurofibromas. Determining such factors could potentially provide a mechanism for surveillance, because 
evaluation for malignant transformation currently does not occur until the tumors produce persistent or increasing 
pain, undergo rapid growth, or cause neurologic deficits (Valeyrie-Allanore et al., 2005). Using a cohort of patients 
systematically assessed for internal neurofibromas by CT scans, Sbidian and colleagues found four variables to be 
independently associated with internal NF: the presence of at least two subcutaneous neurofibromas (odds ratio (OR) 
4.7), age ≤30 years (OR 3.1), absence of cutaneous neurofibromas (OR 2.6), and the presence of fewer than six CALMs 
(OR 2.0). On the basis of OR analyses, these investigators then developed a scoring system to provide a risk prediction 
of the number of patients with internal neurofibromas within a group of patients with NF.
Based on these findings, the above-mentioned patient is at a lower risk of having internal neurofibromas as demon-
strated by the presence of multiple CALMs, cutaneous neurofibromas, and axillary freckling. Through the following 
questions, we examine this paper, as well as the subject of NF-1, in greater detail. For brief answers, please refer to the 
supplementary information online <http://www.nature.com/jid/journal/v130/n9/suppinfo/jid2010225s1.html>.
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